Malignant pleural mesothelioma (MPM) is a heterogeneous cancer composed of distinct molecular and pathologic subtypes. Unfortunately, MPM is aggressive, and current therapies for advanced, unresectable disease remain limited to cytotoxic chemotherapy and immunotherapy. Our understanding of the genomic landscape of MPM is steadily growing, while the discovery of effective targeted therapies in MPM has advanced more slowly than in other solid tumors. Given the prevalence of alterations in tumor suppressor genes in MPM, it has been challenging to identify actionable targets. However, efforts to characterize the genetic signatures in MPM over the last decade have led to a range of novel targeted therapeutics entering early-phase clinical trials. In this review, we discuss the advancements made thus far in targeted systemic therapies in MPM and the future direction of targeted strategies in patients with advanced MPM.
恶性胸膜间皮瘤（MPM）是一种由不同分子和病理亚型组成的异质性癌症。遗憾的是，该疾病具有侵袭性，目前针对晚期不可切除病例的治疗仍局限于细胞毒性化疗和免疫疗法。尽管对MPM基因组特征的认识正在逐步深化，但相较于其他实体肿瘤，MPM有效靶向疗法的研发进展相对缓慢。由于MPM中肿瘤抑制基因突变的高发性，寻找可干预的治疗靶点一直面临挑战。然而，过去十年间对MPM遗传特征的研究已推动多种新型靶向治疗进入早期临床试验阶段。本文综述了目前MPM靶向系统治疗的研究进展，并探讨晚期MPM患者靶向治疗策略的未来发展方向。
Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma
肿瘤(癌症)患者之家